Abstract The changes in the translational repression and variation in mRNA degradation induced by micro RNA are important aspects of tumorigenesis. The association of microRNA-21 with clinicopathologic features and expression of programed cell death 4 (PDCD4) in Iraqi female's with breast tumors has not been studied. MicroRNAs were extracted from a set of 60 breast tumor tissues and blood samples of females with breast cancer and benign breast lesions obtained after breast-reductive surgery, and only blood samples from 30 normal volunteers. These extracts were evaluated for miR-21 expression by quantitative RT-PCR. Analysis of PDCD4 protein expression was carried out as miR-21 target gene by immunohistochemical tests and correlating the results with patients' clinicopathological features. Significant overexpression of miRNA-21 was found in breast cancer group. The fold increase in the miR-21 gene expression was significantly higher in circulating exosomes and breast tissues of breast cancer patients as compared to other groups (P \ 0.001). Overexpression of miR-21 was also significantly associated with the advanced tumor stage and histological grade. In breast cancer patients, PDCD4 protein expression was decreased to about 70% of the level in the control group. The delta Ct of exosomal and breast tissue miRNA-21 was negatively associated with PDCD4 expression. In conclusion, the translational repression of the PDCD4 induced by the high expression of miR-21 promotes breast cell transformation and development of breast tumor, and circulating miR-21 level could be applied to the screening panels for early detection of women breast cancer.
Introduction
The threat of increasing breast cancer incidence in women is of high public concern. One out of eight women is diagnosed with breast cancer during her lifetime, with an estimated 1.57 million new cases in 2012 [1] . The incidence of women breast cancer in Iraq increased from 30/100,000 to 40/100,000 in latest Iraqi cancer registry report and this unimodal increase is distributed homogenously in different geographical regions [2, 3] . Al-Janabi et al. [4] reported that the incidence of breast cancer in the first half of year 2015 increased to exceed half of that for 2014 in Kerbala city in Southern Iraq. Breast cancer worldwide exhibits biological heterogeneity in terms of its prognosis and sensitivity to anti-cancer agents. Numerous studies are currently being conducted in an attempt to identify markers of cell growth and differentiation which are associated with breast cancer formation and progression [5] . MicroRNAs (miRNAs) are small RNA molecules that function in apoptosis, cell proliferation, and cell differentiation [6] [7] [8] . Several cancer-related miRNAs and their target genes have been identified to be either oncopromotors or oncosupressers in tumor cells [9] [10] [11] . MiR-21 is one of the most significantly upregulated miRs in human breast cancer, and its expression contributes to tumor progression and bad prognosis [12] [13] [14] . Evidence suggests that miR-21 targets and inhibits programmed cell death 4 (PDCD4) and other tumor-related genes. Several reports have described the regulation of PDCD4 by miRNA-21 [15] . Asangani et al. [16] found a conserved potential site for miRNA-21 within the 3 -UTR of PDCD4 mRNA. Lu et al. [17] and Zu et al. [18] demonstrated that the implication of the 3 -UTR site as well as the regulation of PDCD4, and that the initiation of invasion and metastasis are promoted by high expression of miRNA-21. MiRNAs are released into the blood by budding or apoptotic and necrotic cells or by active secretion in small particles [19] , and thus, exist in exosomes that are important mediators of cell-cell crosstalk. Lipids, proteins, miRNAs and mRNAs are transferred from one cell to another by exosomes [20] . The tumor cell-derived exosomes have an emerging role in tumor progression and metastases [21] . In this study, and for the first time in Iraq, measured the fold change in both breast tissue and circulating tumor cell-derived (exosomal) miR-21 and its possible impact on the expression of neoplastic transformation inhibitor ''PDCD4'' and further correlated the expression level of miR-21 with the invasiveness of female breast cancer.
Materials and Methods
The study was conducted on 60 female patients (23-67 years) with breast tumors (30 with breast cancer and 30 with benign breast lesions) after getting the approval of the Institutional Review Board at College of Medicine, Al-Nahrain University/Baghdad/Iraq. Blood samples were also taken from thirty age-matched women, who were enrolled in the study as a control group. Written consent was taken from all participants. Patient demographic details, including age, BMI, menopausal status, family history of breast tumors or other malignancies are shown in Table 1 (Supplemented materials).
Five milliliters of blood was aspirated and the sera was fractionated into small tubes for the determination of serum CA 15-3 levels and a portion of the blood was kept in an EDTA tube, centrifuged at 35009g and the plasma was recentrifuged at 10,0009g to remove platelets and cell debris and then stored in a liquid nitrogen at -190°C for subsequent miRNA extraction and molecular analyses.
Breast Tissue Specimens
Resected breast tumors (benign and malignant) and the corresponding apparent normal tissues away from the tumor site were obtained at theatre from those who are scheduled for surgical mastectomy by senior surgeons. Fresh samples were immediately stored in liquid nitrogen for RNA extraction. Breast cancer patients with previous mastectomy, preoperative radiotherapy or chemotherapy were excluded from this study. The whole breast or resected mass was sent to histopathology laboratories for the accurate diagnosis, TNM classification and staging of breast tumors according to the American Joint Committee on Cancer AJCC [22] . Paraffin embedded blocks of these specimens were sectioned for the subsequent immunohistochemical staining and analysis of PDCD4 protein expression.
Determination of Serum Cancer Antigen 15-3 (CA 15-3)
The level of serum CA 15-3 was determined using 50 ll serum samples from each patient and the control group and an Elisa kit for quantitative measurement of human serum CA 15-3 (Human, Germany).
Molecular Analyses

RNA Isolation from Circulating and Tissue Samples
Exosomes were isolated from 600 ll of plasma using the miRCURY TM Exosome Kit (Exiqon, no. 300110, Denmark), that is based on capturing of water molecules which otherwise form the hydrate envelope of particles in suspension. By mixing the sample with the precipitation buffer, dehydration of the particles will favor the precipitation of the subcellular particles below 100 nm at low centrifugation speed. The total RNA and miRNA were extracted from the isolated exosomes using the miRCUR-Y TM RNA Isolation Kit (Biofluids, Exiqon, no. 300112, Denmark), and the RNA was eluted from the column in a final volume of 15 ll.
Total RNA of the breast tumor tissues and the corresponding normal breast tissues were isolated using the miRCURY TM RNA Cell and Plant Isolation Kit (Exiqon, no. 300110, Denmark) and for serum extraction using Biofluid kit (Exiqon, no. 300111, Denmark). For optimal isolation of RNA from breast tissues that have high lipid content, we used Lysis Additive (Exiqon, no. 300121, Denmark) during extraction as suggested by the manufacturer. Tissue homogenization was carried out using a micro pestle motor-driven hand homogenizer on 20 mg of frozen tissue specimen. The homogenate was then passed 5-10 times through a 25 gauge needle attached to a 5 ml syringe to shear genomic DNA prior to loading to the column.
RNA concentration and purity were analyzed using a UV spectrophotometer at A260 and A280 nm and RNA integrity was checked by ethidium bromide stained -2% agarose gel electrophoresis (Figs. 1, 2-Supplemented materials).
One
Step: Reverse Transcription (RT) and Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR)
Each template RNA sample isolated from a tissue or plasma sample was adjusted to a final concentration of 5 ng/ll with nuclease free water and were reverse transcribed to cDNA in 10 ll total reaction volume using Exiqon Universal cDNA synthesis kit (no. 20330, Denmark). These were incubated in a thermal cycle (Clever, UK) that was programed for 42°C for 60 min and 5 min at 95°C, and then maintained at 4°C. Second step RT-qPCR was performed using the ExiLENT SYBR Green master mix (Exiqon no. 203403, Denmark) and LNA TM PCR miR-21 and miR-16 primer sets (Exiqon, Denmark) as reference gene. Four microliters of cDNA diluted to 1:80 (for tissue) or 1:50 for circulating exosomal miRNA were used as templates in a 10 ll total reaction volume using the following conditions: 95°C for 10 min, followed by 40 cycles at 95°C for 10 s, 60°C for 1 min, and a melting curve analysis was carried out at 95°C for 1 min, 55°C for 30 s, 95°C for 30 s. All reactions were carried out on the stratagene (Mx3005P) real-time PCR amplificationdetection system (Agilent Technology, Germany). The expression levels of miR-21 were normalized with the miRNA-16 as reference gene. The relative circulating miRNA quantity was determined using the comparative Ct method. The DCt was calculated by subtracting the Ct values of miRNA-16 from the Ct values of the miRNA-21.The DDCt was used for the determination of fold difference in the miRNA expression which equals to the 2 -DDCt [23] . 
Immunohistochemical Analysis of PDCD4
Immunohistochemical staining for PDCD4 was performed on 5 lm thick formalin fixed paraffin sections of breast tissue specimens after incubation at 37°C for one night and subsequent deparaffinization in xylene and rehydration through different percentages of alcohol. The slides were then treated for blocking endogenous peroxidase activity and nonspecific binding. Afterwards, the sections were incubated at 4°C in a humidified chamber with a monoclonal antibody to PDCD4 at a dilution of 1:200. A twostep technique using universal anti-mouse/anti-rabbit secondary antibody (Abcam, Inc. USA) was used for visualization with the chromogen diaminobenzidine. Finally, sections were counterstained with haematoxylin. Negative controls were performed by replacing the primary antibody with phosphate-buffered saline (PBS). The normal rat liver tissue sample was used as a positive control for PDCD4 ( The staining intensity for PDCD4 in malignant breast cells was assessed as being weak, moderate or strong when compared to the staining intensity observed in benign breast cells [22] .
Statistical Analysis
All statistical analyses were carried out using version 21.0 statistical software (SPSS Inc., Chicago IL, USA). P values \ 0.05 were considered statistically significant. All data were expressed as the mean ± standard error of the mean (SEM). The Student's t test was used to compare between groups' DCt values of microRNAs expression levels. Mann-Whitney-U test was applied for the nonparametric data analysis and the Kruskal-Wallis test was used for more than two independent variables. The diagnostic accuracy of biochemical and molecular markers was performed using the receiver operating characteristic (ROC) curve analysis. The cut off values and area under the ROC curve (AUC) were then determined. Table 1 summarizes data for the histological type, TNM stage, grade, lymph node metastasis, ER, PR and human epidermal growth factor-2 (Her2/neu) status. In this table, of the 30 newly diagnosed breast cancers, twenty (66.7%) samples were having invasive ductal carcinoma, eight (26.5%) with ductal carcinoma in situ (DCIS) and only two (6.7%) showed invasive lobular carcinoma (ILC). The highest percentages of tumors were in the stage II (43.3) and III (43.3%) and 10% were in stage I and 3.3% having stage IV. Regarding the degree of differentiation of the tumor or histological grading, 30% were of grade I, 43.4% of grade II and only 26.7% of tumors were of grade III. The tumor size was less than 2 cm in 56.3% of patients. The lymph node (LN) involvement positive percent was 66.7%, the Her2/neu receptor detection test was negative in 66.7% of the patients, the estrogen receptor (ER) was either positive or negative in 56.7 and 43.3%, respectively, and the progesterone receptor tests were negative in 43.3% and positive in 56.7% of tumor samples.
Results
Results of the Pathological Characteristics of the Patients with Breast Tumors
Results of Serum Cancer Antigen (CA15-3)
The mean ± SEM of the serum CA15-3 concentration was 42.0 ± 3.24 U/ml in breast cancer group, 33.6 ± 1.9 U/ml in benign breast lesion group and 31.2 ± 1.8 U/ml in the control group (Table 2) . Student t test revealed significant increase in the mean values of CA15-3 concentration in breast cancer patients as compared to levels in the control and benign breast lesion groups (P \ 0.01, P \ 0.05, respectively), while no significant difference was observed between benign breast lesions and control groups (P [ 0.05).
Results of Molecular Analyses
The Expression Levels of the Circulating (Exosomal) miRNA-21 and miRNA-16 Among the Studied Groups
The amplification plots of the circulating miRNA-21 and miRNA-16 in control, benign breast lesion and breast cancer groups are presented in Fig. 2 -Supplemented materials.
The mean ± SEM threshold cycle of miRNA-21 and miRNA-16, relative expression and median fold change in the circulating plasma miRNA-21 in the studied groups are shown in Fig. 1 . The circulating level of miRNA-21 was normalized to that of miRNA-16 as a reference gene. The mean ± SEM relative expression (-DCt) value of miRNA-21 was 3.63 ± 0.33 in the breast cancer samples, 0.33 ± 0.15 in benign breast lesion, and 0.11 ± 0.35 in healthy control group.
Statistical analysis revealed a significant increase in the mean of relative expression in the plasma miRNA-21 in breast cancer patients (P \ 0.001) with fold a change of 10.7 as compared with those of the control group, and 14.9-fold change when compared with benign breast lesion (P \ 0.001). No statistically significant difference was observed (P [ 0.05) between these variables in the benign breast lesion as compared to the control group (Fig. 1) .
Result of miRNA-21 and 16 Genes' Expressions in Breast Cancer and Benign Breast Lesion Tissues
As shown in Fig. 2 , the Ct value of miR-21 in breast cancer tissues was lower than that of miR-21 in non-cancer and benign lesion breast tissues, which means that the expression level of miR-21 in breast cancer samples was higher 
The Diagnostics Performance of the Biomarkers in the Studied Groups
Receiver operator characteristics curve (ROC) analysis of tissue miRNA-21 (Fig. 4) in breast cancer patients when compared with benign breast lesion group (Fig. 4a) of the relative expression reading was 0.87. MiRNA-21in plasma of breast cancer patients (Fig. 4b ) recorded lowest sensitivity (93.3%), specificity (83.3%) at cut off value of 1.7. The sensitivity, specificity and best cut off values of relative expression of circulating miRNA-21 in the breast cancer patients when compared with healthy control group were 90, 86.7%, and 1.2, respectively. ROC curve analysis of serum CA 15-3 in malignant breast tumors revealed a low sensitivity and specificity (70 and 56.7%) compared to controls at cut off value 32.5 U/ml whereas in comparison to benign breast lesion, the sensitivity and specificity of serum CA 15-3 were 60 and 50%, respectively at cut off value 33.5 U/ml (Fig. 4c) . Table 3 shows no statistically significant difference in the mean plasma and tissue expression levels of miRNA-21 and serum CA15-3 in breast cancer patients in relation to age at presentation. Twenty invasive ductal carcinoma (NOS) tumors showed highly significant increases in circulating and tissue miRNA-21 expression levels from both ductal carcinoma in situ (DCIS) and invasive lobular carcinoma (ILC) groups (P \ 0.05 and P \ 0.01), also the mean serum CA15-3 was higher in invasive ductal carcinoma (NOS) P = 0.05 (Kruskal-Wallis test). The up-regulated expression of miRNA-21 (plasma and tissue) was associated with advanced TNM stage (P = 0.01 for tissue miRNA-21). In Her-2-positive breast tumors, there were a statistical trend towards decreased levels of circulating miRNAs 21 as compared to Her-2-negative tumor samples (P \ 0.05). Tissue levels of miRNA-21 showed no difference in Her-2 positive and Her-2 negative breast cancer specimens. Whereas, the mean level of serum CA15-3 revealed no significant association and change with the Her-2 status. Fig. 4 The receiver operating characteristic (ROC) curve showing cut off value, sensitivity, specificity and area under curve for a ROC of tissue miRNA-21 in BC group relative to the BBL group (cut off value = 0.87, sensitivity = 100%, specificity = 100%, and area under curve = 1). Plasma miRNA-21 in breast cancer (BC) group relative to the healthy control (HC) group (cut off value = 1.2, sensitivity = 90%, specificity = 86%, and area under curve = 0.93), and in BC group relative to the benign breast lesion (BBL) group (cut off value = 1.7, sensitivity = 93.3%, specificity = 83.3%, and area under curve = 0.94). c serum CA 15-3 in breast cancer with control (cut off value = 32.5, sensitivity = 70%, specificity = 56%, and area under curve = 0.69) and benign breast lesion groups (cut off value = 33.5, sensitivity = 60%, specificity = 50%, and area under curve = 0.639)
Relationship Between MiRNA-21 and CA15-3 in Breast Cancer Patients and Their Clinicopathological Features
Histological Findings for Programed Cell Death 4 (PDCD4) in Malignant and Benign Breast Tissue Lesions
PDCD4-specific staining was positive in all cases of Benign breast tissue samples and the protein was found in both nuclear and cytoplasmic portions (Fig. 5a-f) . In contrary, the PDCD4 specific staining was focused in the cytoplasm of breast cancer cells. The cytoplasmic staining was not as intense as nuclear staining in most breast cancer tissues. Figure 5a , b depict moderate and strong nuclear staining intensities for PDCD4. The invasive ductal carcinoma grade 0 showed negative reaction in the nucleus and cytoplam of less than 10% of cells and loss of positive nucleocytoplasmic reaction (Fig. 5e ). Negative reaction is displayed in the nucleus and cytoplam of invasive ductal carcinoma grade 0 (Fig. 5c ). Staining intensities of 25-50% in grade II invasive ductal carcinoma are shown in Fig. 5d . Loss of positive reaction was observed in the nucleo-cytoplasmic regions of less than 10% of cells invasive lobular carcinoma grade 0 and in ductal carcinoma in situ grade II (Fig. 5f ). PDCD4 was expressed at varying levels in twenty (66.7%) of invasive ductal carcinoma, eight (26.7%) of ductal carcinoma in situ (DCIS) and two (6.7%) cases of Invasive Lobular carcinoma (ILC). Some differences in the distribution and intensity of staining were observed between the groups. In the breast cancer specimens for patients with invasive ductal carcinoma, the immunohistochemical reaction for the detection PDCD4 showed positive expression mainly in cytoplasmic region with few positive expressions in the nucleus (Fig. 5c, d ).
Figure 5c revealed negative expression of PDCD4 in both cytoplasm and nucleus. Breast cancer specimens from the patients with DCIS showed less than 50% positive expression in nucleus and cytoplasm (Fig. 5f) , whereas patients specimens with ILC showed negative PDCD4 expression (Fig. 5e) .
As seen in Table 4 , 90% of specimens from Benign breast tissues exhibit moderate to strong PDCD4 protein expression. Seven out of 30 (23.3%) breast cancer tissues had no detectable PDCD4 protein expression, while 11 out of 30 (36.7%) malignant breast tissues exhibited weak PDCD4 expression and 40% (12/30) showed moderate or strong expression. The overall expression of PDCD4 in breast cancer was significantly lower as compared to Benign breast tissues (P \ 0.01).
Discussion
The present study showed that the highest frequency of breast cancer occurs in Iraqi women with a mean-age of 52 years, while the mean age for women with benign cases and for healthy control was (40 years old). These results were similar to those found by other studies conducted in Iraq; documenting that the malignant breast lesions occur mostly in mean age of 45-51 years [24] [25] [26] and similar mean age prevalence was found in other published reports [27, 28] . The peak age of breast cancer in Asian countries is between 40 and 50 but this still lower than those observed in most developed countries like USA and UK which have a peak age between 60 and 70 years [29] . The high incidence of breast cancer at lower ages than those of developed countries is due to increased exposure to pollution from extensive use of gasoline toward electric generators and the remnants of war and weapons, decreased birth rate, the increase in the age of marriage and probably the westernization of Iraqi diet.
The results of the present study show that the expression level of plasma miRNA-21 was significantly higher (fold change = 10.7, P \ 0.001) in breast cancer patients than in controls and is 14.9 times higher than in the benign breast lesion group. This finding is in line with those reported by Asaga et al. [30] and Mar-Aguilar et al. [31] , who reported that the levels of miR-21 were significantly higher in the sera of breast cancer patients than in the control group and that high-circulating miR-21 concentrations were correlated significantly with the presence and extent of breast cancer. Han et al. [32] found that the serum concentrations of miR-21 was significantly higher in patients with breast cancer as compared to healthy controls. Chen et al. [33] observed that the levels of plasma miR-21 and miR-152 were increased in breast and lung cancer patients.
The expression of miR-21 in breast tissues of breast cancer patients is found to be statistically higher relative to the benign breast lesion group with a median fold change of 11.5. This finding is similar to the results of several other studies that revealed miR-21 expression in breast cancer tissue is significantly higher than those in the normal breast tissue, suggesting that miR-21 functions as an oncogene in cancer development [34, 35] .
Yan et al. [36] found that miR-21 was significantly upregulated in breast cancer. Breast cancer patients with elevated miR-21 expression have the worst prognosis and the high levels of miR-21 appear to be significantly interrelated with the advance of the clinical stage, lymph node metastases, and bad prognosis. Toraih et al. [37] reported high expression of miR-21 in tissues and sera of 30 patients with breast cancer, and 30 cancer-free participants with risk factors for developing breast cancer. The higher levels of serum miR-21 were associated with of high tumors grade, more nodal involvement and advanced clinical stages. Li et al. [38] found that miR-21 was overexpressed in breast cancer tissue in comparison with para-carcinoma site. The circulating miRNA may also play a role in in cell to cell crosstalk and facilitate processes including antigen presentation and hemostasis. Exosomes can release their contents following plasma membrane fusion at target cells. These findings further suggest that exosomes containing miRNAs may have the potential for promoting tumor metastasis and are probable therapeutic targets to treat breast malignancy under diverse pathological conditions [39] [40] [41] .
The sensitivity and specificity of circulating miRNA-21 in breast cancer were found to be 90, 86.7%, respectively, in reference to the control group, and 93, 83.3%, respectively, in relation to the benign breast lesion group. In the study of Gao et al. [42] , the circulating miR-16 and miR-21 were amplified and quantified by real-time PCR in 89 breast cancer patients and 55 healthy controls and they reported a significant increase in circulating miR-21 in breast cancer patients compared to controls (P \ 0.001). The sensitivity and specificity of miR-21 were 87.6 and MiR-21 is considered an 'oncomir' leading to tumorous cell proliferation, apoptosis repression and augmentation of migration, invasion, angiogenesis, and metastasis. The increased miR-21 expression level significantly correlated with tumor grade, tumor size, lymph nodal involvement, lympho-vascular invasion in patients with a worse prognosis. Therapeutic inhibition of miRNAs using a specific antisense oligonucleotide of miR-21 may still be beneficial for a large number of resistant cancers [44] .
PDCD4 gene has the potential of tumor suppression and the PDCD4 can inhibit cell proliferation and promote cell apoptosis through Sp1 transcription factor [45] . The present study demonstrated that the IHC staining for PDCD4 is expressed in both nuclear and cytoplasm fraction of cells but it is abundantly expressed as a cytoplasmic protein in benign breast lesion (90% moderately to strong) cells. Whereas, lower expression of PDCD4 is found more in malignant breast cancer (overall 66.7% weak to strong). The expression of PDCD4 was observed within the epithelial cells of normal breast tissue and in the nucleocytoplasmic fractions. These findings are in agreement with those previously recorded by Wen et al. [46] , who observed a primarily nuclear localization of PDCD4 with decreased protein expression in DCIS compared to normal breast tissues where the PDCD4 expression was predominantly cytoplasmic. PDCD4 is able to the nucleo-cytoplasmic shuttling, and modulate the function of DAXX and therefore it promote DNA damage [47] . The PDCD4 gene product was reported to be the transcription regulator of specific genes through modulating the activity of transcription factors c-Jun, Sp1and p53 [45, 47] . Modelska et al. [48] reported a correlation of PDCD4 with ER expression in breast tumors, specifically the nuclear PDCD4 (q = 0.035). In ER-positive tumors, we observed that the intense PDCD4 positive immunohistochemical staining was associated with lower grade, smaller size and less nodal metastasis in female's breast cancer. In estrogenpositive breast cancers, downregulation of PDCD4 was found to be mediated by upregulation of Her2/neu via the MAPK and Akt signaling pathways, as well as miR-21 in aromatase inhibitor-resistant breast cancer cells [49, 50] .
Furthermore, we recorded low protein expressions of PDCD4 in breast cancer tissues compared to benign breast lesion tissues that was also associated with the increase in the expression of breast cancer tissue and exosomal miR-21. Similar expression of miR-21 and suppression of PDCD4 has been previously reported by Qi et al. [51] who revealed a positive staining of miR-21 in 15 of 17 of IDC specimens with low miR-21 expression in normal tissue (13%), and in flat epithelial atypia, FEA was (47%), 75% in DCIS, and 88% in IDC. The PDCD4 expression was observed in the cytoplasm and nuclei of luminal cells. The expression of PDCD4 was found predominantly in nuclei in normal breast tissue (13 vs. 73% in nucleus, respectively) and FEA (13 vs. 93% in nucleus, in an ordered manner), whereas in DCIS and IDC positive intense cytoplasmic staining was found in nearly 50% of the cases with reduced nuclear staining intensity. However, the nuclear PDCD4 and the miR-21 staining patterns for normal and IDC cases were inversely interrelated. For FEA and DCIS histological types such a relation was not obvious.
The finding of a strong correlation between exosomal and breast tissue miRNA-21 expression in breast tumors (P \ 0.01) pinpoint to the origin of this circulating miRNA-21 and the usefulness of exosomal miRNA determination in screening for breast tumors and as a prognostic marker in these patients.
In conclusion, the increased expression and the interrelation of both breast tissue and exosomal miR-21 in DCIS, and IDC and their inverse correlation with the foremost nuclear expression of PDCD protein signifies the oncogenic role of miR-21 in pathogenesis and the spread of breast cancer in these patients, as well as its potential use as a biomarker for disease screening and response to therapy.
